Literature summary for 3.4.15.1 extracted from

Cesari, M.; Kritchevsky, S.B.; Atkinson, H.H.; Penninx, B.W.; Di Bari, M.; Tracy, R.P.; Pahor, M.
Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the trial of angiotensin converting enzyme inhibition and novel cardiovascular risk factors (TRAIN) study (2009), Am. Heart J., 157, 334e1-334e8.

Search for more literature for 3.4.15.1

Inhibitors

Inhibitors	Comment	Organism	Structure
fosinopril	administered as a prodrug and then rapidly converted by the liver and the gastrointestinal mucosa to the active form fosinoprilat	Homo sapiens
additional information	angiotensin-converting enzyme inhibition does not significantly modify major biomarkers of inflammation, hemostasis, and endothelial function, e.g. C-reactive protein, interleukin 6, plasminogen activator inhibitor 1, vascular cell adhesion molecule 1, and endothelin 1, while angiotensin II levels are reduced, overview	Homo sapiens

Natural Substrates/ Products (Substrates)

Natural Substrates	Organism	Comment (Nat. Sub.)	Natural Products	Comment (Nat. Pro.)	Rev.	Reac.
angiotensin I + H2O	Homo sapiens	i.e. DRVYIHPFHL	angiotensin II + His-Leu	i.e. DRVYIHPF	?

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
angiotensin I + H2O	i.e. DRVYIHPFHL	Homo sapiens	angiotensin II + His-Leu	i.e. DRVYIHPF	?

Synonyms

Synonyms	Comment	Organism
ACE	-	Homo sapiens
angiotensin-converting enzyme	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)